Co-Authors
This is a "connection" page, showing publications co-authored by Hanneke Schuitemaker and Roland Zahn.
Connection Strength
2.407
-
Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP. J Exp Med. 2021 07 05; 218(7).
Score: 0.239
-
Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020; 5:91.
Score: 0.226
-
An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model. Vaccine. 2018 11 12; 36(46):6979-6987.
Score: 0.197
-
Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS One. 2018; 13(8):e0202820.
Score: 0.196
-
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
Score: 0.194
-
Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. NPJ Vaccines. 2018; 3:25.
Score: 0.194
-
A comparative study between outbred and inbred rat strains for the use in in vivo IPV potency testing. Vaccine. 2018 05 17; 36(21):2917-2920.
Score: 0.192
-
Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One. 2018; 13(4):e0196546.
Score: 0.191
-
A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One. 2018; 13(2):e0192312.
Score: 0.189
-
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. Nature. 2021 08; 596(7872):423-427.
Score: 0.060
-
Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques. Cell. 2021 06 24; 184(13):3467-3473.e11.
Score: 0.059
-
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease. NPJ Vaccines. 2021 Mar 19; 6(1):39.
Score: 0.058
-
Coronavirus-Specific Antibody Cross Reactivity in Rhesus Macaques Following SARS-CoV-2 Vaccination and Infection. J Virol. 2021 Mar 10.
Score: 0.058
-
Publisher Correction: Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb; 590(7844):E25.
Score: 0.058
-
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat Med. 2020 11; 26(11):1694-1700.
Score: 0.056
-
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020 10; 586(7830):583-588.
Score: 0.056
-
Adenovirus based HPV L2 vaccine induces broad cross-reactive humoral immune responses. Vaccine. 2018 07 16; 36(30):4462-4470.
Score: 0.048
-
Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response. Hum Gene Ther. 2018 03; 29(3):337-351.
Score: 0.047
-
Development of a replication-deficient adenoviral vector-based vaccine candidate for the interception of HPV16- and HPV18-induced infections and disease. Int J Cancer. 2017 07 15; 141(2):393-404.
Score: 0.045
-
Antigen capsid-display on human adenovirus 35 via pIX fusion is a potent vaccine platform. PLoS One. 2017; 12(3):e0174728.
Score: 0.044